Date: 2014-06-09
Type of information: Production agreement
Compound: allogeneic CART cells
Company: Cellectis (France) CELLforCure (France)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing production
Action mechanism: UCART (for Universal Chimeric Antigen Receptor – T cells) products are allogeneic cell therapy products based on the CAR (Chimeric Antigen Receptor) technology combined with genome engineering. Engineered allogeneic T-lymphocytes bearing a CAR directed at a tumor antigen stand out as a genuine therapeutic innovation in the treatment of various forms of leukemias, lymphomas and solid tumors. UCARTs are “off-the-shelf” allogeneic products. UCARTs’ production can be industrialized and thereby standardized, with consistent pharmaceutical release criteria, over time and from batch to batch. Each future patient may thus be treated by immediately receiving a single dose of a standard product with consistent quality.
Disease:
Details: * On June 9, 2014, Cellectis, a French company dedicated to the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) and CELLforCURE, the largest commercial industrial facility for the production of innovative therapeutic cell therapies in Europe, a subsidiary of the biopharmaceutical group LFB, announce that they have entered into an agreement for the cGMP manufacturing of clinical batches of Cellectis’ allogeneic CART cells. Pursuant to this agreement, CELLforCURE will be responsible for the manufacturing of cGMP clinical batches for candidates from Cellectis’ UCART product family.
Financial terms:
Latest news:
